tbuckley/cabot-search huggingface dataset:
THE NEW ILLINOIS PHARMACY LAW.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cefaclor and serum sickness-like reaction
Authors: R. D. Reynolds
Journal: JAMA (1996)

<h3>In Reply.</h3> —Originally, the serum sickness reaction was described following the administration of horse antiserum. Recently, the serum sickness reaction has been associated with the administration of penicillin, hydralazine, sulfonamides, or thiazide diuretics. This clinical entity results from the formation and deposition of detectable antigen-antibody complexes in blood vessels. Subsequent activation of the immune system and release of vasoactive amines results in clinical disease from 1 to 3 weeks, but usually 7 to 10 days after exposure to the antigen. An urticarial or maculopapular skin rash is the most common sign, occurring 90% of the time. Arthralgias occur in 50% of the cases. Fever, lymphadenopathy, and proteinuria are less frequent. The clinical course is usually benign and resolves quickly after withdrawal of the offending antigen. Epinephrine, antihistamines, and/or steroids may be helpful in more severe cases.<sup>1</sup> From the late 1970s through 1991, Eli Lilly and Co collected and investigated spontaneous reports
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
Authors: David R. Gandara, Sandrine Hiret, George R. Blumenschein, Fabrice Barlesi, Jean-Pierre Delord, Jeannick Madelaine, Jeffrey R. Infante, Karen L. Reckamp, Primo Lara, Christine Audebert, Byoung Chul Cho, Keunchil Park, Fadi S. Braiteh, Robert M. Jotte, Yuehui Wu, Daniel J. Schramek, Alexandra M. Piepszak, Olivia S. Gardner, Vijay Gopal Reddy Peddareddigari, Natasha B. Leighl
Journal: Journal of Clinical Oncology (2013)

8028 Background: KRAS-mutant NSCLC, usually reflecting tobacco-related carcinogenesis, represents an unmet medical need in lung cancer therapy. Trametinib plus docetaxel (doc) enhances growth inhibition and apoptosis of NSCLC cell lines in vitro with and without RAS/RAF mutations when compared with either agent alone. Methods: This 2-part, multiarm, phase I/Ib, open-label study evaluated the safety and efficacy of trametinib plus chemotherapy (NCT01192165). Part 1 determined the recommended phase II dose (RP2D) for trametinib+doc in patients (pts) with advanced solid tumors. In part 2, NSCLC pts were stratified as KRAS WT or mutation unknown (WT) or KRAS-mutant (KRAS) and were treated with trametinib + doc at the RP2D. Primary study objectives were safety and tolerability; secondary objectives were efficacy and pharmacokinetics (PK). Exploratory mutational profiling was done using circulating-free DNA from plasma and available archival tumor tissue. Results: As of January 2013, 46 NSCLC pts (24 WT [67% had ≥ 2 prior therapies] and 22 KRAS [41% had ≥ 2 prior therapies]) have been treated at the trametinib + doc RP2D (2.0 mg + 75 mg/m 2 + growth factors). Diarrhea, fatigue, asthenia, and nausea were the 4 most frequent toxicities. Dose reduction occurred in 10 pts (22%), mostly for diarrhea, fatigue, mucositis, neutropenia, and skin fissures (all 4%). Preliminary PK suggests no drug-drug interaction. In KRAS pts, the best investigator-assessed response (confirmed + unconfirmed) was 3 partial response (PR; RR = 17%) and 8 stable disease (SD; 44%); additionally, 4 pts had &gt; 20% tumor shrinkage. The current disease control rate (DCR) is 61%; 4 pts have not had postbaseline scans. In WT pts, 5 PR (RR=21%) and 11 SD (46%) were observed (67% DCR). Final response and progression-free survival data will be reported upon maturity. Biomarker analyses, including assessment of KRAS mutation subtype vs efficacy, are ongoing. Conclusions: MEK inhibition with trametinib + doc (+ growth factors) demonstrates tolerability and clinical activity in both KRAS-mutant and WT NSCLC, exceeding expectations for each drug alone and warranting further study. Clinical trial information: NCT01192165.
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
Authors: S. A. Rosenberg
Journal: JAMA (1994)

<h3>Objective.</h3> —To determine the efficacy of treatment using high-dose bolus Interleukin 2 (IL-2) in patients with metastatic melanoma or renal cell cancer. <h3>Design and Setting.</h3> —Consecutive series of all patients treated with high-dose IL-2 in the Surgery Branch of the National Cancer Institute from September 1985 through December 1992. <h3>Patients.</h3> —Two hundred eighty-three patients with metastatic melanoma or metastatic renal cell cancer who had failed standard treatment for their cancers. <h3>Interventions.</h3> —Patients received IL-2 at a dose of 720 000 lU/kg intravenously every 8 hours for a maximum of 15 doses per cycle. Two cycles constituted a treatment course, and patients with stable or responding disease received additional treatment courses. A total of 447 courses of treatment were administered. <h3>Main Outcome Measures.</h3> —Regression of measurable tumor, durability of response to treatment, and survival. <h3>Results.</h3> —Nine patients (7%) with metastatic melanoma achieved complete regression of all disease and 14 patients (10%) had partial regression. Ten patients (7%) with metastatic renal cell cancer experienced complete regression and 20 patients (13%) had partial regression. Of the 19 patients with complete regression, 15 have remained in complete remission from 7 to 91 months after treatment. Three treatment-related deaths (1.1%) occurred early in this series, but as experience with the administration of this IL-2 regimen increased, no treatment-related deaths occurred in 214 patients treated during the last 5 years of the study. <h3>Conclusion.</h3> —Biologic therapy with IL-2 can cause significant antitumor effects in patients with advanced metastatic melanoma or renal cell cancer. Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients. (<i>JAMA</i>. 1994;271:907-913)
Preliminary Observations of the Effect of Inhalation of PVC in Man and Experimental Animals
Authors: J. C. Wagner, N. F. Johnson
Journal: Environmental Health Perspectives (1981)

Attention has been focussed, both in man and experimental animals, on the effects of inhalation of the gas monomer, vinyl chloride. Recently, note is being taken of the possible effects of the inhalation of the polymer in man. The particles in question are those produced commercially as paste polymer or dispersion polymer or having an average diameter of 0.15 micrometers, and accounting for more than 10% of the production in Britain. There are now strict regulations for the control of the monomer gas, but the particles are regarded as nuisance dust and their emission is not covered by specific legislation. Our studies on rats, where both inhalation and implantation methods of exposure have been used, and examination of tissue from human cases exposed to paste polymers, indicate that these small particles can only be regarded as evidence of exposure, and on present evidence there is no indication of causation of significant pulmonary disease. Techniques have been developed by which these particles can be demonstrated in ordinary histological preparations and by transmission electron microscopy.
Erratum for the Research Article: “Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance” by W. Roh, P.-L. Chen, A. Reuben, C. N. Spencer, P. A. Prieto, J. P. Miller, V. Gopalakrishnan, F. Wang, Z. A. Cooper, S. M. Reddy, C. Gumbs, L. Little, Q. Chang, W.-S.Chen, K. Wani, M. P. De Macedo, E. Chen, J. L. Austin-Breneman, H. Jiang, J. Roszik, M. T. Tetzlaff, M. A. Davies, J. E. Gershenwald, H. Tawbi, A. J. Lazar, P. Hwu, …
Journal: Science Translational Medicine (2017)
Inflammatory Actions, and their Treatment
Authors: C. H. Jones
Journal: BMJ (1857)

Hospital for the second time in November last.He was dis- charged from the army in 1851, after an attack of " inflamma- tion on the chest".Previously to this, viz., in 1849, he suffered from pleurisy; and when he recovered, he noticed his heart beating " on the wrong side".The surgeon who attended him used frequently to measure his left side, which gradually en.larged.In the autumn of 1850, his breathing was much affected, and his chest was tapped; 110 ounces of clear fluid being taken away.Five weeks later, 86 ounces were removed.A year after, when recovering from an attack of rubeola, 124 ounces were taken away; in another year, 90 ounces; and twelve months later, the same quantity.The last operation was performed in February 1854, when another 90 ounces were withdlrawn.He came in suffering from slight bronchitis, from which he soon recovered; and, although he had made u) his mind to undergo another operation, yet the comparative freedom of his respirationled Dr. Wilson to advise its postponement until more urgent symptoms should alise.He therefore left in the course of two or three weeks.The girth of his chest, which in the sumimier lhad been forty-oine inches, was reduced to thirty- six inchles, as was discovered by the tailor who measured him for at coat prior to his admission.When he went out, the measurement was not miiore than thirtey-five inches.CASE IV.Under the care of W. E. Page, M.D. G. C., a blacksmiiith, aged 37, wlho came in on December 1st, had pleu- risy three years and a half sinice; and great bulging of the left side and constant dyspnuea followed the attack.In five months lbe was tapped, and 66 ounces of clear fluid iwere removed; twvo montlhs later, 156 ounces; three months after this, 96 ounces; in four months, 95 ounces; and finallv, in December 1854, 65 ounces.From this date up to the time of admission he had been constantly at work; only making complaints of " fluid rolling about in his chest" when going, up-hill or up- stairs .Tihe heart was pushed sonmewhat over to the right; and tber-wvas a difference of about three-eighths of an inch between the two sides.His tongue was coated; pulse quickish; face a httle flushed; and respiration slightly hurried.In a dav or two these symptoms vanished; he said that he felt quite wrell; and suddenlly took; it into his head to depart.However, on Jantuary 28th, he again made his appearance, comiplaininlg of increased dyspncea, and giving an account of somiie " itlltammation on the chest" during his absence from the hospital, which attained its height towards the close of the first week in January.The cough and expectoration had not by any means abated, although the breathing was tolerably clear on the right side.
839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
Authors: E.P. Hamilton, S. Goel, R. Arend, C. Chu, D.L. Richardson, J.R. Diamond, V. John, F. Janku, C. Matthews, L. JeBailey, K. Kuida, H. Achour, R. Ruiz-Soto, J. Hays
Journal: Annals of Oncology (2020)
Indications and Contraindications for Exercise Testing
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal of Neurosurgery, Chicago
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MORBUS CERULEUS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SMILE A WHILE
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Harvey Lectures.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infectious diseases
Authors: M. Y. Stoeckle
Journal: JAMA (1994)

The incidence of<i>Haemophilus influenzae</i>type b (Hib) disease in the United States has declined dramatically since the introduction of the Hib vaccination in 1985. In Dallas, Tex, the annual incidence of Hib disease in children younger than 5 years decreased 92%, from 106 cases per 100 000 population in 1983 to nine cases per 100 000 population in 1991.<sup>1</sup>Similar decreases have been documented in multiple geographic areas and in populations at high risk for Hib disease, including Native American children.<sup>2</sup>The profound decrease in disease incidence reflects successful application of Hib conjugate vaccines in young infants and children. The current Hib vaccines contain Hib polysaccharide (polyribosylribitol phosphate [PRP]) conjugated to an immunogenie protein carrier and are administered in three or four doses beginning at 2 months of age. These vaccines include HibTITER (Lederle-Praxis Laboratories, Fairfax, Va), which consists of PRP and diphtheria protein CRM<sub>197</sub>; PedivaxHIB
Delays in access to palliative care services among cancer patients in South Texas.
Authors: Sherri L. Rauenzahn, Susanne Schmidt, Ifeoma Aduba, Nazneen Ali, Laura LaNiel Tenner
Journal: Journal of Clinical Oncology (2017)

215 Background: The growing support for integrated palliative and cancer care resulted in the American Society of Clinical Oncology’s new recommendation which states patients “with advanced cancer should receive dedicated palliative care services, early in the disease course, concurrent with active treatment.” Unfortunately, timely access to palliative services remains an issue for cancer patients and centers. The aim of this project is to evaluate how socioeconomic factors impact palliative access for patients in South Texas. Methods: During a 6-month period, patients in oncology clinics completed the Edmonton Symptom Assessment System questionnaire. Scores reaching a predetermined threshold resulted in a provider alert to consider referral to palliative services. We examine time to initial palliative appointment after referral and compare time to visit based on location of palliative services determined by insurance coverage. Results: During our study period, providers referred 47 unique patients with 27 patients eligible to receive care at the University of Texas Medicine System (Group A) and 20 patients qualified for care at the University Hospital System providing services to under-insured and safety net patients (Group B). Of the 47 referred patients, 27 (57%) patients were offered an appointment and only 17 patients (36%) actually had a palliative care visit (13/27 (48%) Group A patients and 4/20 (20%) Group B patients). On average, Group B patients had 25.2 days longer wait times to palliative visits compared to Group A patients. Conclusions: This investigation revealed a discrepancy between referral and actual receipt of care. While this study is limited by a small sample, data suggests that under-insured oncology patients may have significantly different access to palliative services which may impact the quality of cancer care. [Table: see text]
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas
Authors: Anders Sundin, Natalja Uhlén, Rimma Axelsson
Journal: Clinical Nuclear Medicine (2016)

Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden, Department of Radiology, Uppsala University Hospital, Uppsala, Sweden Department of Clinical Science, Intervention and Technology, Division of Radiography, Karolinska Institutet, Stockholm, Sweden, Department of Radiology, Karolinska University Hospital, Huddinge, Sweden. [email protected] Department of Clinical Science, Intervention and Technology, Division of Medical Imaging and Technology, Karolinska Institutet, Stockholm, Sweden, Department of Radiology, Karolinska University Hospital, Huddinge, Sweden Conflicts of interest and sources of funding: none declared.
Medical Education
Authors: Robert G. Petersdorf
Journal: JAMA (1990)

Essential to any discussion about medical education in the future are the following three topics: the students, the educational process, and its content. Perhaps one of the most heartening events that the Association of American Medical Colleges, Washington, DC, can report is the apparent reversal of the decline in the number of young men and women who are applying to medical school. From 1974, when applicants for the entering class numbered more than 42 600, until 1988, when fewer than 27 000 applied, the number of applicants to medical schools declined by more than one third. No one hypothesis seems to explain fully the decline, and the profession has been justifiably concerned about why young people no longer find medicine attractive. However, the situation is now looking brighter. The number of applicants for 1989 showed a 0.7% increase from the previous year (Association of American Medical Colleges, unpublished data, 1979).